{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:41:00Z","timestamp":1792035660923,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes","award":["PWD&RPP-MRI, JYY2023-6"],"award-info":[{"award-number":["PWD&RPP-MRI, JYY2023-6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04007-9","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:15:20Z","timestamp":1774257320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity"],"prefix":"10.1007","volume":"46","author":[{"given":"Ziyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"3","key":"4007_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY et al (2017) TFOS DEWS II epidemiology report. Ocul Surf 15(3):334\u2013365","journal-title":"Ocul Surf"},{"issue":"2","key":"4007_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ajo.2013.10.014","volume":"157","author":"M Uchino","year":"2014","unstructured":"Uchino M, Uchino Y, Dogru M et al (2014) Dry eye disease and work productivity loss in visual display users: the Osaka study. Am J Ophthalmol 157(2):294\u2013300","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"4007_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/jamaophthalmol.2022.4394","volume":"140","author":"P McCann","year":"2022","unstructured":"McCann P, Abraham AG, Mukhopadhyay A et al (2022) Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States: a systematic review and meta-analysis. JAMA Ophthalmol 140(12):1181\u20131192","journal-title":"JAMA Ophthalmol"},{"key":"4007_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-9-111","volume":"9","author":"L Abetz","year":"2011","unstructured":"Abetz L, Rajagopalan K, Mertzanis P et al (2011) Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes 9:111","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"4007_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","volume":"30","author":"J Yu","year":"2011","unstructured":"Yu J, Asche CV, Fairchild CJ (2011) The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 30(4):379\u2013387","journal-title":"Cornea"},{"issue":"2","key":"4007_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.clindermatol.2015.11.009","volume":"34","author":"MM McCusker","year":"2016","unstructured":"McCusker MM, Durrani K, Payette MJ et al (2016) An eye on nutrition: the role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. Clin Dermatol 34(2):276\u2013285","journal-title":"Clin Dermatol"},{"issue":"6","key":"4007_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061618","volume":"13","author":"A Ballesteros-S\u00e1nchez","year":"2024","unstructured":"Ballesteros-S\u00e1nchez A, S\u00e1nchez-Gonz\u00e1lez JM, Tedesco GR et al (2024) Evaluating GlicoPro tear substitute derived from Helix aspersa snail mucus in alleviating severe dry eye disease: a first-in-human study on corneal esthesiometry recovery and ocular pain relief. J Clin Med 13(6):66","journal-title":"J Clin Med"},{"issue":"12","key":"4007_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123277","volume":"11","author":"D Borroni","year":"2023","unstructured":"Borroni D, Mazzotta C, Rocha-de-Lossada C et al (2023) Dry eye para-inflammation treatment: evaluation of a novel tear substitute containing hyaluronic acid and low-dose hydrocortisone. Biomedicines 11(12):66","journal-title":"Biomedicines"},{"issue":"2","key":"4007_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40123-023-00868-w","volume":"13","author":"A Ballesteros-S\u00e1nchez","year":"2024","unstructured":"Ballesteros-S\u00e1nchez A, S\u00e1nchez-Gonz\u00e1lez JM, Tedesco GR et al (2024) Efficacy and safety of quantum molecular resonance electrotherapy in patients with aqueous-deficient, evaporative and mixed-type dry eye: a randomized interventional study. Ophthalmol Ther 13(2):495\u2013507","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"4007_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40123-023-00877-9","volume":"13","author":"A Ballesteros-S\u00e1nchez","year":"2024","unstructured":"Ballesteros-S\u00e1nchez A, S\u00e1nchez-Gonz\u00e1lez JM, Borrone MA et al (2024) The influence of lid-parallel conjunctival folds and conjunctivochalasis on dry eye symptoms with and without contact lens wear: a review of the literature. Ophthalmol Ther 13(3):651\u2013670","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"4007_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051424","volume":"11","author":"C Garc\u00eda-L\u00f3pez","year":"2022","unstructured":"Garc\u00eda-L\u00f3pez C, G\u00f3mez-Huertas C, S\u00e1nchez-Gonz\u00e1lez JM et al (2022) Opioids and ocular surface pathology: a literature review of new treatments horizons. J Clin Med 11(5):66","journal-title":"J Clin Med"},{"issue":"4","key":"4007_CR12","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","volume":"52","author":"KK Nichols","year":"2011","unstructured":"Nichols KK, Foulks GN, Bron AJ et al (2011) The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 52(4):1922\u20131929","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"4007_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","volume":"100","author":"C Baudouin","year":"2016","unstructured":"Baudouin C, Messmer EM, Aragona P et al (2016) Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol 100(3):300\u2013306","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4007_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jtos.2017.01.006","volume":"15","author":"G Geerling","year":"2017","unstructured":"Geerling G, Baudouin C, Aragona P et al (2017) Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: proceedings of the OCEAN group meeting. Ocul Surf 15(2):179\u2013192","journal-title":"Ocul Surf"},{"issue":"1","key":"4007_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/ICL.0000000000000680","volume":"46","author":"PY Lam","year":"2020","unstructured":"Lam PY, Shih KC, Fong PY et al (2020) A review on evidence-based treatments for meibomian gland dysfunction. Eye Contact Lens 46(1):3\u201316","journal-title":"Eye Contact Lens"},{"issue":"4","key":"4007_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40265-024-02016-5","volume":"84","author":"A Zhuang-Yan","year":"2024","unstructured":"Zhuang-Yan A, Syed YY (2024) Perfluorohexyloctane ophthalmic solution: a review in dry eye disease. Drugs 84(4):441\u2013448","journal-title":"Drugs"},{"issue":"5","key":"4007_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1246\/bcsj.20170431","volume":"91","author":"X Liu","year":"2018","unstructured":"Liu X, Riess JG, Krafft MP (2018) Self-organization of semifluorinated alkanes and related compounds at interfaces: thin films, surface domains and two-dimensional spherulites. Bull Chem Soc Jpn 91(5):846\u2013857","journal-title":"Bull Chem Soc Jpn"},{"issue":"4","key":"4007_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041211","volume":"15","author":"C Tsagogiorgas","year":"2023","unstructured":"Tsagogiorgas C, Otto M (2023) Semifluorinated alkanes as new drug carriers-an overview of potential medical and clinical applications. Pharmaceutics 15(4):66","journal-title":"Pharmaceutics"},{"issue":"3","key":"4007_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/jop.2019.0092","volume":"36","author":"D Schmidl","year":"2020","unstructured":"Schmidl D, Bata AM, Szegedi S et al (2020) Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther 36(3):154\u2013161","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"4007_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/ICO.0000000000002622","volume":"40","author":"J Tauber","year":"2021","unstructured":"Tauber J, Wirta DL, Sall K et al (2021) A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea 40(9):1132\u20131140","journal-title":"Cornea"},{"issue":"5","key":"4007_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","volume":"130","author":"J Tauber","year":"2023","unstructured":"Tauber J, Berdy GJ, Wirta DL et al (2023) NOV03 for dry eye disease associated with Meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology 130(5):516\u2013524","journal-title":"Ophthalmology"},{"key":"4007_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","volume":"252","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Kurata F, Epitropoulos AT et al (2023) NOV03 for signs and symptoms of dry eye disease associated with Meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol 252:265\u2013274","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"4007_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamaophthalmol.2023.0270","volume":"141","author":"L Tian","year":"2023","unstructured":"Tian L, Gao Z, Zhu L et al (2023) Perfluorohexyloctane eye drops for dry eye disease associated with Meibomian gland dysfunction in Chinese patients: a randomized clinical trial. JAMA Ophthalmol 141(4):385\u2013392","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"4007_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0161-6420(97)30125-0","volume":"104","author":"OD Schein","year":"1997","unstructured":"Schein OD, Tielsch JM, Mun\u00f5z B et al (1997) Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology 104(9):1395\u20131401","journal-title":"Ophthalmology"},{"issue":"11","key":"4007_CR25","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jamaophthalmol.2021.3943","volume":"139","author":"EJ Holland","year":"2021","unstructured":"Holland EJ, Jackson MA, Donnenfeld E et al (2021) Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: a post hoc analysis of 2 randomized clinical trials. JAMA Ophthalmol 139(11):1200\u20131208","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"4007_CR26","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/bjophthalmol-2013-304619","volume":"98","author":"C Baudouin","year":"2014","unstructured":"Baudouin C, Aragona P, Van Setten G et al (2014) Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol 98(9):1168\u20131176","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"4007_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M et al (2016) Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 26(4):287\u2013296","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"4007_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","volume":"141","author":"EK Akpek","year":"2023","unstructured":"Akpek EK, Wirta DL, Downing JE et al (2023) Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial. JAMA Ophthalmol 141(5):459\u2013466","journal-title":"JAMA Ophthalmol"},{"key":"4007_CR29","doi-asserted-by":"crossref","unstructured":"Kaercher T, Sheppard JD, Hamm A et al (2024) Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease. Graefes Arch Clin Exp Ophthalmol","DOI":"10.1007\/s00417-024-06688-3"},{"issue":"10","key":"4007_CR30","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","volume":"40","author":"JD Sheppard","year":"2021","unstructured":"Sheppard JD, Wirta DL, McLaurin E et al (2021) A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study. Cornea 40(10):1290\u20131297","journal-title":"Cornea"},{"issue":"7","key":"4007_CR31","first-page":"2966","volume":"65","author":"J Sheppard","year":"2024","unstructured":"Sheppard J, Vittitow JL, Cavet M et al (2024) Efficacy of perfluorohexyloctane ophthalmic solution in patients with dry eye disease stratified by baseline severity. Investig Ophthalmol Vis Sci 65(7):2966","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4007_CR32","doi-asserted-by":"publisher","first-page":"1452422","DOI":"10.3389\/fopht.2024.1452422","volume":"4","author":"AM Fahmy","year":"2024","unstructured":"Fahmy AM, Harthan JS, Evans DG et al (2024) Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials. Front Ophthalmol (Lausanne) 4:1452422","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"4007_CR33","doi-asserted-by":"crossref","unstructured":"Gu H, Li Z, Zhu L (2025) Factors Associated With Perfluorohexyloctane Treatment Response in Dry Eye Disease Associated With Meibomian Gland Dysfunction. Cornea","DOI":"10.1097\/ICO.0000000000003927"},{"issue":"3","key":"4007_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK et al (2017) TFOS DEWS II pathophysiology report. Ocul Surf 15(3):438\u2013510","journal-title":"Ocul Surf"},{"issue":"5","key":"4007_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0161-6420(99)00513-8","volume":"106","author":"Z Liu","year":"1999","unstructured":"Liu Z, Pflugfelder SC (1999) Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 106(5):939\u2013943","journal-title":"Ophthalmology"},{"issue":"9","key":"4007_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1089\/jop.2017.0042","volume":"33","author":"P Steven","year":"2017","unstructured":"Steven P, Augustin AJ, Geerling G et al (2017) Semifluorinated alkane eye drops for treatment of dry eye disease due to Meibomian gland disease. J Ocul Pharmacol Ther 33(9):678\u2013685","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"4007_CR37","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1097\/ICO.0000000000003418","volume":"43","author":"EE Protzko","year":"2024","unstructured":"Protzko EE, Segal BA, Korenfeld MS et al (2024) Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI study. Cornea 43(9):1100\u20131107","journal-title":"Cornea"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04007-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:02:51Z","timestamp":1774299771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04007-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4007"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04007-9","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was done in accordance with the Declaration of Helsinki. The trial protocol was approved by the ethics committees of participating hospitals (No. TREC2020-50).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants or their guardians before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"171"}}